<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C"><gtr:id>BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C</gtr:id><gtr:name>Waters Corporation / Micromass U K Ltd</gtr:name><gtr:address><gtr:line1>Floats Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:line4>Manchester</gtr:line4><gtr:postCode>M23 9LZ</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Health and Population Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C"><gtr:id>BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C</gtr:id><gtr:name>Waters Corporation / Micromass U K Ltd</gtr:name><gtr:address><gtr:line1>Floats Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:line4>Manchester</gtr:line4><gtr:postCode>M23 9LZ</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/90300D17-7BE0-4E54-B57F-4F4569547B87"><gtr:id>90300D17-7BE0-4E54-B57F-4F4569547B87</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Stewart</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AA7589C1-0DF6-41E7-9965-D48B53606E62"><gtr:id>AA7589C1-0DF6-41E7-9965-D48B53606E62</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Hewison</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6C9E8964-E317-44D9-9833-EB9C7D2DE4D6"><gtr:id>6C9E8964-E317-44D9-9833-EB9C7D2DE4D6</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Gittoes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100729"><gtr:id>F30D0363-A319-4917-B8B9-4B52610197F7</gtr:id><gtr:title>Pre-receptor metabolism and the control of hormone action</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100729</gtr:grantReference><gtr:abstractText>Hormones are chemicals that are released from endocrine glands into the circulation to act on a number of tissues and organs throughout the human body. However, different parts of the body respond differently to hormones, and one reason for this is that enzymes are present in tissues that can change hormones between active and inactive states. Thus an enzyme that activates a hormone will cause high levels of hormone action in that part of the body and this occurs independent of any change in circulating hormone levels. Our group has expertise in the workings of these enzymes and we now believe that they may be involved in causing human disease. Obesity and osteoporosis (thin bones), are major health hazards affecting up to 20% of the population. Breast and prostate cancers are also leading causes of death in the UK. In each case there are examples of hormones being important in causing these diseases, but in the majority of cases, hormone levels are normal within the blood. However, we have shown that an alteration in enzymes within key tissues such as cancers, fat and bone tissue may affect local hormone levels and contribute to the underlying disease. Importantly, new therapies that specifically target these enzymes may offer exciting future treatments for these common diseases. This research group will combine expertise to further define the role of a series of enzymes responsible for hormone action. In doing so, we believe we can make significant head way into the causes of, and therapy for, cancer, obesity and osteoporosis.</gtr:abstractText><gtr:technicalSummary>Steroid and thyroid hormones play a pivotal role in the physiology and pathophysiology of diverse tissues. The transregulatory actions of steroid hormones are dependent on the expression of cognate intracellular receptors and post-receptor activator and repressor proteins. However, regulation of hormone action is also achieved at a pre-receptor level through a series of metabolic enzymes expressed in a tissue-specific fashion. This is particularly evident in tissues such as adipose and bone, as well as various tumours, where hormones such as cortisol, thyroid hormone and 1,25-dihydroxyvitamin D3 (1,25D3) exert pluripotent regulatory effects. In previous studies we have characterized the expression of enzymes involved in glucocorticoid, thyroid and vitamin D hormone metabolism;11b-hydroxysteroid dehydrogenases (11b-HSDs), iodothyronine deiodinases (deiodinase) and vitamin D-1a-/24-hydroxylases, respectively. Furthermore, as a consequence of functional studies in vivo and in vitro we have hypothesized that the autocrine production of glucocorticoids, thyroid hormone and vitamin D is involved in the pathogenesis of prevalent human diseases such as hypertension, obesity, osteoporosis and cancer. The aim of this Co-operative Group (COG) will be to develop a multidisciplinary collaborative group with a common interest in the metabolism of steroid/thyroid hormones. The COG will be to establish core facilities to undertake a sensitive analysis of steroid and thyroid hormones with the objective of elucidating new mechanisms and developing novel therapeutic targets, to a broad range of clinical problems central to the Health of the Nation.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>345982</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Waters Corporation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>New Biomarker analysis</gtr:description><gtr:id>DF50E447-7C41-407D-BC8E-867AE84B0B5C</gtr:id><gtr:impact>New Gas chromatography/ mass spectrometry platforms established. Helped pump prime new MRC Biomarkers grant on adrenal tumours</gtr:impact><gtr:outcomeId>A9D94512BC4-1</gtr:outcomeId><gtr:partnerContribution>New Gas chromatography/ mass spectrometry platforms established. Helped pump prime new MRC Biomarkers grant on adrenal tumours</gtr:partnerContribution><gtr:piContribution>Established GC/MS steroid technology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>plenary and symposia lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5925E109-61F9-49C3-864C-487FBD98E1FA</gtr:id><gtr:impact>Presentation to large audiences at International meetings

Local radio, press releases. Discipline specific press releases at conferences</gtr:impact><gtr:outcomeId>EEFCAB2F628</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1032652</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant (Hexose-6-phosphate dehydrogenase and Glucose-6-phosphate: novel regulators of corticosteroid hormone metabolism and adrenal function). (Ref: 082809).</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>082809</gtr:fundingRef><gtr:id>9752AEEE-4547-4757-BEB9-F3DCA3E63B37</gtr:id><gtr:outcomeId>56C9168C2440</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>159135</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>&amp;quot;Local glucocorticoid metabolism in inflammatory arthritis&amp;quot;. October 2007 for 3 years (Ref: 18081).</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>082809</gtr:fundingRef><gtr:id>4F1700EF-CBD8-4BBF-AEE9-1E58D46C85CC</gtr:id><gtr:outcomeId>1E76C35F7C80</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>168107</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>&amp;quot;Corticosteroid hormone action in cardiomyocytes - impact on heart failure&amp;quot;, October 2006 for 3 years (MRC Fellowship to Dr Fabian Hammer) (Ref: G0600432).</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0600432</gtr:fundingRef><gtr:id>07128133-A61D-4B33-9475-EA6D8781D707</gtr:id><gtr:outcomeId>4016D29010F0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>916094</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Steroid Profiling as a Biomarker Tool in the Diagnosis and Monitoring of Adrenal Tumours</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801473</gtr:fundingRef><gtr:id>6ADCEA6D-30C8-47A8-9381-59CEA773125A</gtr:id><gtr:outcomeId>HphrJUwiMUk0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>298510</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Experimental Medicine grant &amp;quot;Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1: A novel treatment for the Metabolic Syndrome&amp;quot;, April 2006 for 3 years (Ref: G0502165).</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0502165</gtr:fundingRef><gtr:id>6559F9EB-14A0-4935-B895-7F7FCA66A45F</gtr:id><gtr:outcomeId>638FC5AC3CE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>371657</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>&amp;quot;11beta-hydroxysteroid dehydrogenase type 1, growth hormone and the pathophysiology of age related sarcopaenia&amp;quot;. May 2007 for 3 years (MRC Fellowship to Dr Mark Sherlock) (Ref: G0601429).</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0601429</gtr:fundingRef><gtr:id>84F451F0-096B-4DB2-9A3E-6FAAB4DACB16</gtr:id><gtr:outcomeId>4844A91FFE50</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Helped develop selective 11beta hydroxysteroid dehydrogenase 1 inhibitors for use in Obesity-Diabetes Mellitus. Several phase II trials have been conducted - none led by Stewart but Stewart involved in a few.</gtr:description><gtr:id>6C7AA288-215B-4A8F-93DE-CC27B1ED587B</gtr:id><gtr:impact>Many Pharma companies in development phase after our original pre clinical work. MRC-AZ collaboration now involves AZ 4017 which is an 11HSD1 inhibitor</gtr:impact><gtr:outcomeId>31A242342AF</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>11HSD1 inhibitors</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>In vivo assessment steroid metabolism in patients with Metabolic syndrome. Gold standard for diagnosis of inherited steroid disorders. Evaluation as diagnostic for adrenal cancer patients (see Arlt W ...... Stewart PM, J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84)</gtr:description><gtr:id>524FA97F-9617-420E-9C8C-7B990EC18FF7</gtr:id><gtr:impact>Widespread adoption for drug efficacy studies</gtr:impact><gtr:outcomeId>6F452654F1C</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>GC/MS</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of gas chromatography/ mass spectrometry analysis of steroids - helped human phenotyping</gtr:description><gtr:id>00FC8F7E-F05C-4751-93C2-D1F0475D9841</gtr:id><gtr:impact>Adrenal biomarkers for diagnostic purposes</gtr:impact><gtr:outcomeId>0FFD8D5405A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GC/MS</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7706E353-FC49-40B4-B7B9-7E5EF1E2F545</gtr:id><gtr:title>High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>5899cc5ff28a72.05872234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE56D245-B4C2-4210-A629-B002C27A26F1</gtr:id><gtr:title>11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/013fb76c9f158ebf6e606b94ae6c6a63"><gtr:id>013fb76c9f158ebf6e606b94ae6c6a63</gtr:id><gtr:otherNames>Walker EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>E14FC10DF76</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>185C6ABD-3793-49FD-80A9-32667916A5F9</gtr:id><gtr:title>Male 11?-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74757ba33a4f5d12d4ab5eea50de0695"><gtr:id>74757ba33a4f5d12d4ab5eea50de0695</gtr:id><gtr:otherNames>Larner DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>5899cccc346691.00551550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78B1886E-1AED-4520-A34C-5AE2B47F43F9</gtr:id><gtr:title>Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes.</gtr:title><gtr:parentPublicationTitle>Journal of molecular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89761595fc43d00a1b253082a82baea3"><gtr:id>89761595fc43d00a1b253082a82baea3</gtr:id><gtr:otherNames>Bujalska IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0952-5041</gtr:issn><gtr:outcomeId>7047E780E43</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4AD1F04-FB24-4E4A-BAD4-E5BBB21ACAC3</gtr:id><gtr:title>Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/015b14afa6b5b3668d14f53b709742c8"><gtr:id>015b14afa6b5b3668d14f53b709742c8</gtr:id><gtr:otherNames>Weigel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>5899ccce911dd5.94872711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E5FEEE3-ACCC-4E31-8652-77B4A922D8FF</gtr:id><gtr:title>Glucocorticoid-induced apoptosis in human decidua: a novel role for 11beta-hydroxysteroid dehydrogenase in late gestation.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bb910383a7ac63892c5757b9c0a846e"><gtr:id>0bb910383a7ac63892c5757b9c0a846e</gtr:id><gtr:otherNames>Chan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>46B693C009B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18B7DE42-938C-4473-A77A-AAEF346CC72B</gtr:id><gtr:title>11?-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd3c2f45f3b8f27357013fb43d184259"><gtr:id>cd3c2f45f3b8f27357013fb43d184259</gtr:id><gtr:otherNames>Doig CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>5a9e6fb56aefe8.35955257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C813618-9F58-4CDC-B867-85981ACDCDA2</gtr:id><gtr:title>Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5d8ef8943d35a20e95fca492fd3713e"><gtr:id>b5d8ef8943d35a20e95fca492fd3713e</gtr:id><gtr:otherNames>Stewart PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>5899ccccb7c184.28270689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CC698A7-D79E-4877-87BB-0CF29DAD40E5</gtr:id><gtr:title>11?-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d98bf3954a69fc156c27af9fb0725e"><gtr:id>88d98bf3954a69fc156c27af9fb0725e</gtr:id><gtr:otherNames>Hardy RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5899ccce1275a6.73528981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>259882ED-0F6A-4CA2-8C12-BBDF64176A61</gtr:id><gtr:title>SFRP2 Is Associated with Increased Adiposity and VEGF Expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6faad224b0d9f2591b7db726f3b40c7a"><gtr:id>6faad224b0d9f2591b7db726f3b40c7a</gtr:id><gtr:otherNames>Crowley RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5899cccd4ab794.53893970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1261F5A-3D05-41AB-B048-E6F7A6F564AE</gtr:id><gtr:title>Glucocorticoids and 11?-HSD1 are major regulators of intramyocellular protein metabolism.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50266dbb5bd134a51e37cc9434e56cf3"><gtr:id>50266dbb5bd134a51e37cc9434e56cf3</gtr:id><gtr:otherNames>Morgan SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>5899cccb289589.72720995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95CA65C0-EED1-4D60-8E9D-0683656B73D3</gtr:id><gtr:title>Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7416d802fac8c54a0a20f10e58737ab1"><gtr:id>7416d802fac8c54a0a20f10e58737ab1</gtr:id><gtr:otherNames>Gathercole LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>6C520FF3FC4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22C95E1D-98BE-4E56-9AD8-DB683AE2F27D</gtr:id><gtr:title>Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfa08c2a75ffac43dcfc6bc9fac293d"><gtr:id>ebfa08c2a75ffac43dcfc6bc9fac293d</gtr:id><gtr:otherNames>Arlt W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>CDF51A1683D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB2BED82-D7B1-4999-A09A-5D75D37AB500</gtr:id><gtr:title>Hypoglycemia with enhanced hepatic glycogen synthesis in recombinant mice lacking hexose-6-phosphate dehydrogenase.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a440c1edea41fd8b10866dc9f79cdbc8"><gtr:id>a440c1edea41fd8b10866dc9f79cdbc8</gtr:id><gtr:otherNames>Lavery GG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>D72C725590F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD6E3114-145B-4082-94C4-D863C73999E3</gtr:id><gtr:title>Characterisation of 11beta-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89761595fc43d00a1b253082a82baea3"><gtr:id>89761595fc43d00a1b253082a82baea3</gtr:id><gtr:otherNames>Bujalska IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>907A373B3A2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED294ADD-3453-4737-B95C-2F2FE9FEE966</gtr:id><gtr:title>Acromegaly.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01dc0ed26132145d0eddfb05f09f7965"><gtr:id>01dc0ed26132145d0eddfb05f09f7965</gtr:id><gtr:otherNames>Dineen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>5899cc38528dc8.91468951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ACE7DC4-ED7D-4D0D-A563-AB5DED21E0B5</gtr:id><gtr:title>25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 exert distinct effects on human skeletal muscle function and gene expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f09044e3f91aa3a457592847b93ab33"><gtr:id>8f09044e3f91aa3a457592847b93ab33</gtr:id><gtr:otherNames>Hassan-Smith ZK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a9e6fb53ac910.74640781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE7AD1FC-3B3C-41E0-A9B2-BF104DB725A5</gtr:id><gtr:title>Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe897a89ac5436707fd5b6aef0a3e357"><gtr:id>fe897a89ac5436707fd5b6aef0a3e357</gtr:id><gtr:otherNames>Tomlinson JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>6770B7D7618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1DC9019-3389-4D36-94EB-30D33EE80402</gtr:id><gtr:title>Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a440c1edea41fd8b10866dc9f79cdbc8"><gtr:id>a440c1edea41fd8b10866dc9f79cdbc8</gtr:id><gtr:otherNames>Lavery GG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>68EFCFECBD0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1B1E751-BB86-4DAF-B3B8-71752840A63C</gtr:id><gtr:title>Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3371bf5bd214349b10832ad888e2b5a7"><gtr:id>3371bf5bd214349b10832ad888e2b5a7</gtr:id><gtr:otherNames>Clayton RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn><gtr:outcomeId>5899cccbaf37b7.12024305</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100729</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>